Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Shaw, Executive Chairperson of Biocon & Biocon Biologics, said the pharma industry faces long 'lab-to-market' timelines, high ...

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has released the transcript of its Q1 FY26 earnings call, which was held on ...

Biocon will target an initial public offering in India in late 2023. Pennsylvania-based Viatris will have the right to name on director to the Biocon board and will appoint its President, Rajiv ...

Biocon Biologics, a unit of Biocon (BION.NS), said Hulio would be available at a list price of 5% below Humira's current list price. Humira comes at list price of $6,922 per carton.

Biocon Biologics said it will acquire Viatris’ Biosimilars Assets for up to $3.335 billion in stock and cash, according to a statement. The acquisition provides the company with access to ...

Shares of Indian drugmaker Biocon Ltd fell about 12% on Monday after the company said its unit Biocon Biologics would buy U.S.-based Viatris Inc's biosimilars business in a transaction valued at ...

Biocon Ltd.’s shares fell the most in more than a year after the Indian drugmaker consolidated its long-standing bet on the pioneering field of complex medicines with a $3.3 billion deal to buy ...

Biocon has learnt from the industry, says Harish Iyer, head of research and development. He cites the example of Januvia, a drug for type II diabetes from Merck that is hailed for its marketing ...